Advancing Alpha Radioligand Therapies into the Clinic: Lessons Learned from Building a First-in-Human Development Programme

• Sharing the development journey of AB001 from discovery and preclinical development through Phase 0 and into Phase I clinical evaluation
• Exploring the clinical, regulatory and CMC considerations required to successfully transition alpha radioligand therapies into the clinic
• Evaluating the manufacturing and supply challenges associated with short-lived radionuclides, including the implications of a 10.5-hour half-life on clinical execution

Speakers: